Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00824226
NCT00824226CompletedNot Applicable

Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients

University of Tartu1 site in 1 country10 target enrollmentStarted: January 1, 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
10
Locations
1
Primary Endpoint
Calcium level at the end of magnesium treatment compared to pretreatment level
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •primary or secondary hypoparathyroidism
  • •treatment with calcium plus vitamin D analogue
  • •ionized calcium 1,0-1,29 mmol/L
  • •magnesium level 0,7-1,05 mmol/L
  • •TSH 0.1- 10 imU/L

Exclusion Criteria

  • •any other disease known to influence plasma Ca level
  • •pregnancy
  • •creatinine > 150 microM/L
  • •patient has used supplementary magnesium within 2 previous months

Outcomes

Primary Outcomes

Calcium level at the end of magnesium treatment compared to pretreatment level

Time Frame: 3 weeks

Secondary Outcomes

  • Calcium level after stopping treatment compared to the level at the end of magnesium treatment(2 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Vallo Volke

Dr.

University of Tartu

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on HaemodialysisEndstage Renal Disease
NCT02977117Iain Bressendorff59
Recruiting
Not Applicable
The Impact of Dialysate Magnesium on the Calcification Propensity of SerumN18.5Chronic kidney disease, stage 5
DRKS00005230Abteilung für Nephrologie, Medizinische Klinik Bürgerspital Solothurn35
Completed
Not Applicable
Magnesium and Platelet Function TestingEclampsia Preeclampsia
NCT03143647Ziekenhuis Oost-Limburg20
Unknown
Not Applicable
Ratio of Dietary Calcium to Magnesium on Cardiovascular RiskCardiovascular Risk FactorNutritional and Metabolic DiseasesHypertension
NCT04531267Guangdong Provincial People's Hospital42
Completed
Not Applicable
Decreased blood calcium levels following thyroid operation - does magnesium play a role?
CTRI/2013/12/004195Fluid research grant50